BR112022001368A2 - Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos - Google Patents

Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos

Info

Publication number
BR112022001368A2
BR112022001368A2 BR112022001368A BR112022001368A BR112022001368A2 BR 112022001368 A2 BR112022001368 A2 BR 112022001368A2 BR 112022001368 A BR112022001368 A BR 112022001368A BR 112022001368 A BR112022001368 A BR 112022001368A BR 112022001368 A2 BR112022001368 A2 BR 112022001368A2
Authority
BR
Brazil
Prior art keywords
proteins
antigen
kallikrein
binding domains
related peptidase
Prior art date
Application number
BR112022001368A
Other languages
English (en)
Inventor
Degang Song
Fang Yi
Fei Shen
Jinquan Luo
John Lee
Rajkumar Ganesan
Raymond Brittingham
Sanjaya Singh
Sathyadevi Venkataramani
Lynn La Porte Sherry
Theresa Mcdevitt
Yonghong Zhao
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112022001368A2 publication Critical patent/BR112022001368A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464458—Proteinases
    • A61K39/46446—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos. as modalidades da presente invenção fornecem proteínas isoladas que compreendem domínios de ligação ao antígeno que se ligam à peptidase 2 relacionada à calicreína (hk2), incluindo anticorpos monoespecíficos e biespecíficos. modalidades adicionais da invenção fornecem polinucleotídeos que codificam as proteínas específicas de hk2, vetores, células hospedeiras e métodos de preparo e uso dos mesmos.
BR112022001368A 2019-07-26 2020-07-23 Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos BR112022001368A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962878964P 2019-07-26 2019-07-26
US201962910650P 2019-10-04 2019-10-04
US202063030445P 2020-05-27 2020-05-27
PCT/IB2020/056972 WO2021019389A1 (en) 2019-07-26 2020-07-23 Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

Publications (1)

Publication Number Publication Date
BR112022001368A2 true BR112022001368A2 (pt) 2022-05-24

Family

ID=71895039

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001368A BR112022001368A2 (pt) 2019-07-26 2020-07-23 Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos

Country Status (19)

Country Link
US (2) US12077585B2 (pt)
EP (1) EP4004057A1 (pt)
JP (2) JP2022541332A (pt)
KR (1) KR20220040483A (pt)
CN (1) CN114375302A (pt)
AU (1) AU2020322222A1 (pt)
BR (1) BR112022001368A2 (pt)
CA (1) CA3147735A1 (pt)
CL (2) CL2022000142A1 (pt)
CO (1) CO2022001891A2 (pt)
CR (1) CR20220025A (pt)
DO (1) DOP2022000013A (pt)
EC (1) ECSP22015276A (pt)
IL (1) IL289897A (pt)
MX (1) MX2022001049A (pt)
PE (1) PE20220649A1 (pt)
TW (1) TW202118788A (pt)
UY (1) UY38803A (pt)
WO (1) WO2021019389A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202118788A (zh) 2019-07-26 2021-05-16 美商健生生物科技公司 包含血管舒緩素相關肽酶2抗原結合域之蛋白質及其用途
CA3184189A1 (en) * 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
WO2022013818A1 (en) * 2020-07-17 2022-01-20 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-klk2 antibodies
EP4284446A2 (en) * 2021-01-27 2023-12-06 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
TW202304988A (zh) 2021-03-24 2023-02-01 美商健生生物科技公司 靶向ＣＤ７９ｂ、ＣＤ２０、及ＣＤ３之三特異性抗體
KR20230163485A (ko) * 2021-03-31 2023-11-30 얀센 바이오테크 인코포레이티드 면역 이펙터 세포 재유도를 위한 물질 및 방법
MX2023014069A (es) * 2021-05-27 2024-03-15 Janssen Biotech Inc Composiciones y métodos para el tratamiento del cáncer de próstata.
MX2024010339A (es) 2022-02-23 2024-09-30 Xencor Inc Anticuerpos anti-cd28 x anti-psma.
WO2024089551A1 (en) * 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
CN117187180B (zh) * 2023-11-03 2024-01-26 四川大学 一种Th17细胞及其培养方法和应用及其诱导液

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU736419B2 (en) 1996-07-15 2001-07-26 Hybritech Inc. Methods to detect HK2 polypeptides
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2005075662A2 (en) * 2004-01-28 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
CN102307594A (zh) 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
NZ601171A (en) 2010-03-31 2014-11-28 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
PT2771364T (pt) 2011-10-27 2019-09-10 Genmab As Produção de proteínas heterodiméricas
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
EP2794905B1 (en) 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
JP2015528003A (ja) 2012-07-13 2015-09-24 ザイムワークス，インコーポレイテッド 抗ｃｄ３構築物を含む二重特異性の非対称ヘテロ二量体
EP3653049B1 (en) 2012-12-14 2023-09-13 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
SG11201507577RA (en) 2013-03-15 2015-10-29 Janssen Biotech Inc Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
LT3071595T (lt) 2013-11-19 2019-05-10 Fredax Ab Humanizuotas anti-kalikreino-2 antikūnas
GB2520353A (en) * 2013-11-19 2015-05-20 Fredax Ab Antibody polypeptides and uses thereof
AU2015373910B2 (en) 2015-01-02 2021-11-18 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor XII
IL284985B2 (en) 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
AR106365A1 (es) 2015-10-02 2018-01-10 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
EP3377117A1 (en) 2015-11-18 2018-09-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
JP7022123B2 (ja) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に対する二重特異性抗体
KR20200012859A (ko) * 2017-04-26 2020-02-05 유레카 쎄라퓨틱스, 인코포레이티드 키메라 활성화 수용체 및 키메라 자극 수용체를 발현하는 세포 및 그의 용도
SG11202002533QA (en) 2017-09-22 2020-04-29 Kite Pharma Inc Chimeric polypeptides and uses thereof
SG11202011270QA (en) * 2018-05-24 2020-12-30 Janssen Biotech Inc Anti-cd3 antibodies and uses thereof
EP4004055A1 (en) 2019-07-26 2022-06-01 Janssen Biotech, Inc. Anti-hk2 chimeric antigen receptor (car)
TW202118788A (zh) 2019-07-26 2021-05-16 美商健生生物科技公司 包含血管舒緩素相關肽酶2抗原結合域之蛋白質及其用途
EP4284446A2 (en) 2021-01-27 2023-12-06 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Also Published As

Publication number Publication date
WO2021019389A1 (en) 2021-02-04
CL2022000142A1 (es) 2022-10-07
CL2023000499A1 (es) 2023-08-04
TW202118788A (zh) 2021-05-16
DOP2022000013A (es) 2022-07-15
KR20220040483A (ko) 2022-03-30
MX2022001049A (es) 2022-05-03
US12077585B2 (en) 2024-09-03
CA3147735A1 (en) 2021-02-04
AU2020322222A1 (en) 2022-03-24
IL289897A (en) 2022-03-01
CO2022001891A2 (es) 2022-04-08
CR20220025A (es) 2022-05-04
UY38803A (es) 2021-01-29
JP7506817B2 (ja) 2024-06-26
PE20220649A1 (es) 2022-04-28
CN114375302A (zh) 2022-04-19
US20210040210A1 (en) 2021-02-11
JP2022541332A (ja) 2022-09-22
US20240124583A1 (en) 2024-04-18
EP4004057A1 (en) 2022-06-01
JP2024026260A (ja) 2024-02-28
ECSP22015276A (es) 2022-03-31

Similar Documents

Publication Publication Date Title
BR112022001368A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
BR112021026376A2 (pt) Proteínas de fusão flt3l-fc e métodos de uso
ECSP17054182A (es) Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123
EA202190435A1 (ru) Конструкции на основе антител для связывания cldn18.2 и cd3
CL2019002310A1 (es) Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797)
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
MX2020000435A (es) Anticuerpos anti-cd166 y usos de estos.
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
BRPI0610796B8 (pt) anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
BR112022026575A2 (pt) Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413
BR112022004570A2 (pt) Terapia de combinação com anticorpos entpd2 e cd73
WO2019118906A3 (en) Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
AR119468A1 (es) Proteínas que comprenden dominios de unión antígeno de la peptidasa 2 relacionados con la calicreína y sus usos
WO2024184702A3 (en) Vh4-34 antigen-binding molecules
AR128013A1 (es) Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf
AR119982A1 (es) Terapias de combinación con anticuerpos entpd2
MX2024006969A (es) Anticuerpos dlk1 y metodos de tratamiento del cancer.
WO2024040114A3 (en) Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
EA202091458A1 (ru) Анти-trem2 антитела и связанные с ними способы